提前时间偏倚不能否定前列腺癌复发早期挽救放疗的疗效
研究纳入603例根治性前列腺切除术后复发接受挽救放疗的患者,分别从手术时间和放疗时间计算结局。多因素分析显示放疗前PSA是生化进展和无进展生存的显著预测因素,且从手术时间计算仍成立,不支持提前时间偏倚否定早期挽救放疗优势的假说。
要点
- 放疗前PSA<0.4 ng/ml是生化进展和无进展生存的显著区分因素。
- 从手术时间计算结局时,放疗前PSA对生化进展和无进展生存仍有显著影响。
- 总生存分析未找到放疗前PSA的显著截断值,可能因事件数过少。
核心结论
- 放疗前PSA对生化进展、无进展生存及潜在总生存有显著影响,无论从根治性前列腺切除时间还是挽救放疗时间计算结局,均不支持提前时间偏倚否定早期挽救放疗优势的假说。
研究设计与样本
- 回顾性分析1997至2017年间603例根治性前列腺切除术后复发并接受挽救放疗的前列腺癌患者,分别从放疗时间和手术时间计算结局。
主要发现
- 多因素分析中,pT3-4、病理Gleason评分(GS≤6 vs GS 7 vs GS≥8)、术后PSA持续(nadir≥0.1 ng/ml)及放疗前PSA(连续或截断值0.4 ng/ml)是挽救放疗后和根治性前列腺切除术后生化进展和无进展生存的显著危险因素。
- 放疗前PSA<0.4 ng/ml是生化进展和无进展生存Kaplan-Meier率的显著区分因素。
- 总生存Cox模型纳入根治性前列腺切除时年龄(连续)、pT2 vs pT3-4及放疗前PSA(连续)为显著预测因素,但未找到放疗前PSA区分总生存Kaplan-Meier估计的显著截断值,可能因事件数过少,末次随访时88%患者仍存活。
关键数值与推荐
- 放疗前PSA<0.4 ng/ml为生化进展和无进展生存的显著区分截断值。
- 术后PSA持续定义为nadir≥0.1 ng/ml。
临床怎么用
- 前列腺癌根治性切除术后复发患者,放疗前PSA<0.4 ng/ml与更好的生化进展和无进展生存相关,支持早期挽救放疗。
局限性
- 总生存分析事件数过少,末次随访时88%患者仍存活,可能影响总生存截断值的识别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In prostate cancer (PCa) recurring after radical prostatectomy (RP), salvage radiotherapy (SRT) is recommended to be given at PSA <0.5 ng/ml. It has been speculated, that the advantage from early SRT is mainly caused by lead-time bias: Calculating from time of SRT, earlier treatment would per-se result in longer time to event/censoring compared with later treatment, but not extend the interval from RP to post-SRT failure. METHODS: In 603 consecutive PCa patients receiving SRT between 1997 and 2017, we compared outcomes, calculating from time of irradiation vs. time of surgery. RESULTS: In multivariable analysis, tumor stage pT3-4, pathological Gleason score GS ≤6 vs. GS 7 vs. GS ≥8, post-RP PSA persistence (nadir ≥0.1 ng/ml), and the pre-SRT PSA (continuous or with cutoff 0.4 ng/ml) were significant risk-factors for biochemical progression (BCR) and progression-free survival (PFS) post-SRT and post-RP. A pre-SRT PSA <0.4 ng/ml was a significant discriminator for Kaplan-Meier rates of BCR and PFS. The Cox model for overall survival (OS) included age at RP (continuous), pT2 vs. pT3-4, and pre-SRT PSA (continuous) as significant predictors. However, no significant cutoff for the pre-SRT PSA could be identified to differentiate Kaplan-Meier estimates of OS, possibly because there were too few events, as 88% of the patients were still alive at last follow-up. CONCLUSIONS: The pre-SRT PSA has a significant impact on BCR, PFS and potentially on OS, calculating either from RP or from SRT to event/censoring, respectively. This contradicts the hypothesis of lead-time bias falsifying the advantage from early SRT.
引用
- Bartkowiak D, Thamm R, Siegmann A, et al. Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer. Radiother Oncol. 2020. PMID: 32920006. doi:10.1016/j.radonc.2020.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。